Integration and acquisition costs	12 Months Ended
Dec. 31, 2014
IntegrationAndAcquisitionCosts[Abstract]
Integration and acquisition costs	6. Integration and acquisition costs For the year to December 31, 2014 Shire recorded integration and acquisition costs of $158.8 million (2013: a net credit of $134.1 million, 2012: $13.5 million), comprising costs of $144.1 million primarily related to the acquisition and integration of ViroPharma and a net charge of $14.7 million relating to the change in fair values of contingent consideration liabilities. The change in fair value of contingent consideration liabilities in the year to December 31, 2014 principally relates to the acquisition of SARcode, reflecting Shire's increased confidence in the SHP606 program and the acquisition of FerroKin, reflecting the decision to place the ongoing Phase 2 clinical trial for SHP602 on clinical hold. In the year to December 31, 2013 integration and acquisition costs primarily related to the acquisitions of SARcode and Lotus Tissue Repair Inc. (“Lotus Tissue Repair”) in addition to net charges related to the change in fair values of contingent consideration liabilities.

Integration and acquisition costs

12 Months Ended

Dec. 31, 2014

IntegrationAndAcquisitionCosts[Abstract]

6. Integration and acquisition costs

For the year to December 31, 2014 Shire recorded integration and acquisition costs of $158.8 million (2013: a net credit of $134.1 million, 2012: $13.5 million), comprising costs of $144.1 million primarily related to the acquisition and integration of ViroPharma and a net charge of $14.7 million relating to the change in fair values of contingent consideration liabilities. The change in fair value of contingent consideration liabilities in the year to December 31, 2014 principally relates to the acquisition of SARcode, reflecting Shire's increased confidence in the SHP606 program and the acquisition of FerroKin, reflecting the decision to place the ongoing Phase 2 clinical trial for SHP602 on clinical hold.

In the year to December 31, 2013 integration and acquisition costs primarily related to the acquisitions of SARcode and Lotus Tissue Repair Inc. (“Lotus Tissue Repair”) in addition to net charges related to the change in fair values of contingent consideration liabilities.